COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations

• 作者: Marco Morrone Matteo Scotto Di Vetta Serafino Fazio
• 来源期刊: 世界荟萃分析杂志
• 学科: 医学
• 关键词: COVID-19 Evidence based medicine Hydroxycloroquine Azithromycine Indomethacine DOXYCYCLINE
• 年，卷（期）: 2020,（3）
• 页码范围: 173-177
• 页数: 5页
• 分类号: R95

摘要

The world pandemic due to coronavirus disease 2019,known as COVID-19,embodies a high rate of disease transmission that causes a critical hospitalization overload.As of May 15,2020,the disease has been the cause of more than 4 million infections and more than 280000 deaths all over the world.At the beginning,we underestimated the disease;now,we have sufficient information and it is clear that it is not just a respiratory disease.In fact,if a prompt treatment is not initiated,the disease may evolve towards an abnormal immune response and cytokine storm with an important thrombophilic pattern.Therefore,we think that while waiting for certainties to be established by evidence-based medicine,it is not ethical to not try off-label therapies for some of the well-known drugs,as they could have some efficacy based on their mechanisms of action.